EN DE
Watch Monte Rosa Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Monte Rosa Therapeutics Inc (GLUE) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Monte Rosa Therapeutics Inc stock $7.16, price $9.16, that is 21.8% below the price, quality 45 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US61225M1027

MR Monte Rosa Therapeutics Inc logo Thin data Nov 17, 2026

Monte Rosa Therapeutics Inc

GLUE · US

Expensive (fair value 22% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Quality 45/100 
Mixed Growth (revenue YoY +63.5 %/yr in USD) 
Mixed vs. peers (4/9) 
Insiders sold $2.5M (6M) 
Fair value $7.16 · Overvalued 
Falling price (downtrend) 
Loss-making · -186.2% net margin (TTM) 
Negative free cash flow 
Narrow moat 8/100 · thin data
Recent news very negative 
Thin data 
Estimate
Watch Monte Rosa Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$42.21 $2.50 Fair Value $7.16 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $2.50 – $42.21 · fair‑value band $5.37 – $8.95 · the $9.16 price screens above the $7.16 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Monte Rosa Therapeutics in your weekly email

Every Wednesday you see whether Monte Rosa Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.

Show moreShow less

The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.

In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases.

The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis.

The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Stock analysis

Monte Rosa Therapeutics Inc (GLUE) currently trades at $9.16, while our estimate is $7.16, 22% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.37 (bear) to $8.95 (bull), the price of $9.16 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Monte Rosa Therapeutics Inc reported revenue of $124M in FY2025 versus $0 in FY2021. Reported net income was −$38.6M in FY2025.

Key figures

Market cap $803M Small · P/S ratio 12.9 · EPS (TTM) $−1.39 · Net margin −31.2% · Return on equity −35.3% · Return on assets (EBIT) −26.1% (5-year average) · Operating margin −3.6% · Revenue (TTM) $70.3M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 64% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −22%, GLUE screens richer than that median.

Fair Value

Bear $5.37 Fair Value $7.16 Bull $8.95
Price $9.16 · Downside -21.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 98
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 81
Does it invest with discipline instead of growing at any price?
Low Volatility 16
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 27
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors sold shares worth $2.5M and none bought.

  • SaleMatthew BowenPrincipal Accounting Officer13 shares at $10.56$137Oct 5, 2026
  • SaleMarkus WarmuthPresident & CEO, Director7× since Jan 5, 2026: 49,500 shares, avg. $19.21$951,078Jul 16, 2026
  • SaleJennifer ChampouxChief Operating Officer6× since Jan 5, 2026: 15,682 shares, avg. $19.85$311,296Jul 15, 2026
  • SaleSharon TownsonChief Scientific Officer5× since Jan 5, 2026: 21,155 shares, avg. $20.04$423,933Jul 6, 2026
  • SaleFilip JankuChief Medical Officer5× since Jan 5, 2026: 65,596 shares, avg. $21.03$1.4MJun 30, 2026
  • SaleAnthony M. ManningDirector2× since May 21, 2026: 20,000 shares, avg. $20.56$411,200Jun 29, 2026
  • SalePhilip NicksonChief Business & Legal Officer2× since Jan 5, 2026: 9,000 shares, avg. $16.81$151,259Apr 9, 2026
  • SaleEdmund DunnPrincipal Accounting Officer3× since Jan 5, 2026: 26,878 shares, avg. $17.97$483,106Mar 4, 2026

Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GLUE screens overvalued: fair value 22% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Monte Rosa Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −21.8% · Above median
Profitability
Return on assets −8.6% · Above median
Net margin (12 months) −186.2% · Bottom 25%
Operating margin (12 months) −3.6% · Below median
Growth and dividend
Revenue growth (quarter YoY) 325.8% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.45× · Pricier than median
P/S (12 months) 11.42× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)4 · sector 0
FUTURE (revenue growth)100 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs GLUE
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs GLUE
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs GLUE
argenx SE ARGX $950.95 $908.40 −4% vs GLUE
CSL Limited CSL A$199.55 A$186.49 −7% vs GLUE
Moderna, Inc MRNA $215.27 $135.64 −37% vs GLUE
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs GLUE
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs GLUE
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs GLUE
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs GLUE

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Monte Rosa Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Monte Rosa Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/GLUE

Frequently asked questions

Is Monte Rosa Therapeutics Inc (GLUE) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $7.16 versus a price of $9.16, about 22% lower (overvalued).
What is the fair value of GLUE?
Our estimate for Monte Rosa Therapeutics Inc is $7.16 (as of Nov 17, 2026), built from audited fundamentals. The current price: $9.16.
What is the quality score of GLUE?
Monte Rosa Therapeutics Inc has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Monte Rosa Therapeutics Inc (GLUE)?
Our calculated price target is the estimate of $7.16 (as of Nov 17, 2026). Cautious scenario $5.37, optimistic scenario $8.95. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Monte Rosa Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $7.16, about 22% lower versus a price of $9.16 (overvalued). Cautious scenario $5.37, optimistic scenario $8.95. The calculation is refreshed regularly with new filings.
What is the revenue of Monte Rosa Therapeutics Inc (GLUE)?
Monte Rosa Therapeutics Inc reported trailing-twelve-month revenue of about $70.3M (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Monte Rosa Therapeutics Inc (GLUE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Monte Rosa Therapeutics Inc it is $7.16 per share (as of Nov 17, 2026), against a price of $9.16.
Is Monte Rosa Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 17, 2026, GLUE trades above its calculated fair value: price $9.16, fair value $7.16, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GLUE?
No. The price is what the market pays today ($9.16); the fair value is what the company's own numbers justify ($7.16). For Monte Rosa Therapeutics Inc the two are $2.00 per share apart. That gap is exactly why we show both numbers side by side.
How much is Monte Rosa Therapeutics Inc worth?
The market values Monte Rosa Therapeutics Inc at about $803M (market capitalisation, as of Nov 17, 2026). Per share that is $9.16; our models calculate a fair value of $7.16 per share.
What do the bullish and bearish scenarios say about GLUE?
Our models span a range for Monte Rosa Therapeutics Inc: cautious scenario $5.37, base $7.16, optimistic $8.95 per share (as of Nov 17, 2026, price $9.16). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Monte Rosa Therapeutics Inc (GLUE)?
Balance-sheet figures for Monte Rosa Therapeutics Inc (as of Nov 17, 2026): return on equity −35.3%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is GLUE from its 52-week high?
Monte Rosa Therapeutics Inc trades at $9.16, about 64% below its 52-week high of $25.31 and at the low of $9.16 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $7.16 is for.
Which stocks are comparable to Monte Rosa Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Monte Rosa Therapeutics Inc stock attractive at the current price?
The data as of Nov 17, 2026: price $9.16, calculated fair value $7.16 (−22%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Monte Rosa Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Monte Rosa Therapeutics Inc (GLUE)?
The closing price on Nov 16, 2026 was $9.16. Our estimate is $7.16, about 22% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Monte Rosa Therapeutics Inc right now?
The price sits above even our optimistic bull case ($8.95). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Monte Rosa Therapeutics Inc

How large is the market capitalisation of Monte Rosa Therapeutics Inc (GLUE)?
The market capitalisation of Monte Rosa Therapeutics Inc is $803M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Monte Rosa Therapeutics Inc (GLUE)?
The price-to-sales ratio of Monte Rosa Therapeutics Inc is 12.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Monte Rosa Therapeutics Inc (GLUE)?
Earnings per share at Monte Rosa Therapeutics Inc are $−1.39. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Monte Rosa Therapeutics Inc (GLUE)?
The net margin of Monte Rosa Therapeutics Inc is −31.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Monte Rosa Therapeutics Inc (GLUE)?
The return on equity (ROE) of Monte Rosa Therapeutics Inc is −35.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Monte Rosa Therapeutics Inc (GLUE)?
On an EBIT basis the return on assets of Monte Rosa Therapeutics Inc is −26.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Monte Rosa Therapeutics Inc (GLUE)?
The operating margin of Monte Rosa Therapeutics Inc is −3.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Monte Rosa Therapeutics Inc (GLUE)?
Revenue at Monte Rosa Therapeutics Inc is growing 326% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Monte Rosa Therapeutics Inc (GLUE) generate?
The free cash flow of Monte Rosa Therapeutics Inc is −$27.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Monte Rosa Therapeutics Inc (GLUE) hold?
Monte Rosa Therapeutics Inc holds more cash than debt, $90.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Monte Rosa Therapeutics Inc in the live analysis

One click puts Monte Rosa Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.